What is SUN GENOMICS?
Sun Genomics operates at the intersection of biotechnology and personalized wellness, offering a novel approach to improving gut health. The company's flagship product, Floré, empowers consumers to understand their unique gut microflora through stool analysis. Leveraging DNA sequencing technology, Sun Genomics formulates bespoke probiotic blends tailored to individual needs, delivering them directly to customers. This direct-to-consumer model, coupled with a continuous feedback loop that allows customers to track improvements over time via retesting, positions Sun Genomics as a leader in the burgeoning personalized nutrition market. The company's mission is to enhance well-being through science-driven, individualized solutions.
How much funding has SUN GENOMICS raised?
SUN GENOMICS has raised a total of $12.3M across 2 funding rounds:
Angel/Seed
$3.1M
Series A
$9.3M
Angel/Seed (2019): $3.1M, investors not publicly disclosed
Series A (2020): $9.3M led by SOSV LLC, K3 Ventures, Human Longevity Inc, Nascita Ventures, Pangaea Ventures Ltd, and Danone Manifesto Ventures Inc
Key Investors in SUN GENOMICS
Pangaea Ventures Ltd
Pangaea Ventures Ltd is a venture capital firm specializing in hard tech, focusing on investments in start-up companies that utilize advancements in materials, chemistry, and biology to tackle significant global challenges. Their impact model aligns with the United Nations Sustainable Development Goals, ensuring measurable outcomes from their investments.
K3 Ventures
K3 Ventures is an investment firm that provides capital and strategic support to companies. Their focus often includes technology and growth-stage businesses, aiming to foster innovation and market leadership through their backing.
SOSV LLC
SOSV LLC is a venture capital firm that operates a portfolio of accelerator programs and invests in early-stage companies across various sectors, including biotech and life sciences, providing both funding and operational support.
What's next for SUN GENOMICS?
With the recent infusion of major strategic capital, Sun Genomics is poised for significant growth and innovation. The enterprise-level backing suggests a focus on scaling operations, expanding research and development into new areas of microbiome science, and potentially broadening its product portfolio. This investment will likely enable the company to enhance its DNA sequencing capabilities, refine its formulation algorithms, and increase its market reach. Sun Genomics' ability to create a closed-loop system for personalized probiotic delivery and efficacy tracking provides a strong foundation for sustained expansion and leadership in the personalized health sector.
See full SUN GENOMICS company page
